Firoozeh Shahidi, MD
Endocrinology, Diabetes & Metabolism · Falls Church, VANPI 1619058674
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 262 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$692
- Amneal Pharmaceuticals LLC$689
- Lilly USA, LLC$651
- Novo Nordisk$616
- AbbVie$421
- Radius Health, Inc.$232
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,78099%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 38 | $692 |
| Amneal Pharmaceuticals LLC | 39 | $689 |
| Lilly USA, LLC | 38 | $651 |
| Novo Nordisk | 33 | $616 |
| AbbVie(2 entities) | 27 | $421 |
| Radius Health, Inc. | 11 | $232 |
| IBSA Pharma Inc. | 10 | $203 |
| Amgen | 7 | $150 |
| Exact Sciences | 5 | $113 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| AstraZeneca(2 entities) | 4 | $93 |
| Boehringer Ingelheim | 4 | $78 |
| Antares Pharma, Inc. | 4 | $75 |
| Amarin Pharma, Inc. | 4 | $71 |
| Recordati_rare_diseases_inc. | 2 | $62 |
| Mannkind Corporation | 4 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| EUSA Pharma (US) LLC | 1 | $48 |
| Johnson & Johnson | 2 | $45 |
| Astellas Pharma US Inc | 2 | $44 |
| BETA Bionics, Inc. | 2 | $43 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $36 |
| Pfizer | 2 | $31 |
| Tandem Diabetes Care, Inc. | 2 | $28 |
| Novartis | 1 | $26 |
| Acella Pharmaceuticals, LLC | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Halozyme Inc | 1 | $20 |
| Avion Pharmaceuticals | 1 | $18 |
| Medtronic | 1 | $18 |
| Merck | 1 | $16 |
How this compares
$4,836 in reported general payments places this provider in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $94,186 |
| OzempicSemaglutide | 44 | $72,728 |
| TymlosAbaloparatide | 12 | $39,913 |
| JardianceEmpagliflozin | 16 | $26,907 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $19,024 |
| VascepaIcosapent Ethyl | 17 | $17,255 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $14,001 |
| LinzessLinaclotide | 18 | $11,775 |
| SynthroidLevothyroxine Sodium | 101 | $11,177 |
| AliskirenAliskiren Hemifumarate | 12 | $3,169 |
| Rosuvastatin Calcium | 102 | $2,210 |
| Nebivolol Hcl | 20 | $2,067 |
| Ezetimibe | 61 | $1,520 |
| Bupropion XlBupropion Hcl | 31 | $1,470 |
| Buspirone Hcl | 12 | $1,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $651 | $94,18681 claims |
| Novo NordiskOzempic | $616 | $72,72844 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $78 | $40,90834 claims |
| Radius Health, Inc.Tymlos | $232 | $39,91312 claims |
| AbbVieLinzess, Synthroid | $421 | $22,952119 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $689 | $1,381132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Falls Church
- Pedram JavanmardFalls Church$6K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.